Wells Fargo has raised its price target for Incyte (INCY) to $116 while maintaining an &#34;Overweight&#34; rating, reflecting an optimistic outlook after a 19.59% increase from the previous target. This follows a series of upward revisions by various analysts, suggesting strong market confidence in the biotechnology company. The average analyst target for INCY is $95.28, with an average brokerage recommendation of 2.3, indicating &#34;Outperform&#34; status.

INCY

<p>Wells Fargo has raised its price target for Incyte (INCY) to $116 while maintaining an "Overweight" rating, reflecting an optimistic outlook after a 19.59% increase from the previous target. This follows a series of upward revisions by various analysts, suggesting strong market confidence in the biotechnology company. The average analyst target for INCY is $95.28, with an average brokerage recommendation of 2.3, indicating "Outperform" status.</p>

INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News